Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.
Daldegan-Bueno D, Donegan CJ, Forsyth A, Sumner RL, Murphy RJ, Menkes DB, Evans W, Hoeh N, Sundram F, Reynolds LM, Ponton R, Cavadino A, Smith T, Roop P, Allen N, Abeysinghe B, Svirskis D, Bansal M, Muthukumaraswamy S. Daldegan-Bueno D, et al. Trials. 2024 Aug 24;25(1):560. doi: 10.1186/s13063-024-08384-3. Trials. 2024. PMID: 39182140 Free PMC article.
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).
Donegan CJ, Daldegan-Bueno D, Sumner R, Menkes D, Evans W, Hoeh N, Sundram F, Reynolds L, Ponton R, Cavadino A, Smith T, Roop P, Allen N, Abeysinghe B, Svirskis D, Forsyth A, Bansal M, Muthukumaraswamy S. Donegan CJ, et al. Among authors: daldegan bueno d. Pilot Feasibility Stud. 2023 Oct 5;9(1):169. doi: 10.1186/s40814-023-01399-8. Pilot Feasibility Stud. 2023. PMID: 37798662 Free PMC article.
LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals.
Wießner I, Falchi M, Daldegan-Bueno D, Palhano-Fontes F, Olivieri R, Feilding A, B Araujo D, Ribeiro S, Bezerra Mota N, Tófoli LF. Wießner I, et al. Among authors: daldegan bueno d. Eur Neuropsychopharmacol. 2023 Mar;68:89-104. doi: 10.1016/j.euroneuro.2022.12.013. Epub 2023 Jan 19. Eur Neuropsychopharmacol. 2023. PMID: 36669231 Clinical Trial.
Ayahuasca's therapeutic potential: What we know - and what not.
Maia LO, Daldegan-Bueno D, Wießner I, Araujo DB, Tófoli LF. Maia LO, et al. Among authors: daldegan bueno d. Eur Neuropsychopharmacol. 2023 Jan;66:45-61. doi: 10.1016/j.euroneuro.2022.10.008. Epub 2022 Nov 8. Eur Neuropsychopharmacol. 2023. PMID: 36368095 Review.
Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis.
Robinson T, Ali MU, Easterbrook B, Coronado-Montoya S, Daldegan-Bueno D, Hall W, Jutras-Aswad D, Fischer B. Robinson T, et al. Among authors: daldegan bueno d. Drug Alcohol Depend. 2022 Sep 1;238:109582. doi: 10.1016/j.drugalcdep.2022.109582. Epub 2022 Jul 21. Drug Alcohol Depend. 2022. PMID: 35932748 Review.
26 results